Correlation Engine 2.0
Clear Search sequence regions

  • androgen (10)
  • androgen antagonists (2)
  • degarelix (1)
  • gnrh (1)
  • gonadotropin (3)
  • humans (1)
  • patients (1)
  • phases (1)
  • physicians (1)
  • prostate (2)
  • Sizes of these terms reflect their relevance to your search.

    Androgen deprivation therapy (ADT) has been a treatment of choice for prostate cancer in almost all phases, particularly in the locally advanced, metastatic setting in both hormone-sensitive and castration-resistant diseaseand in those who are unfit for any local therapy. Different ways of administering ADT comes in the form of surgical or chemical castration with the use of gonadotropin-releasing hormone (GnRH-agonists) being the foremost way of delivering ADT. This review encompasses ADT history, use of leuprolide, degarelix, and relugolix, with contextual use of ADT in combination with androgen-signaling inhibitors and potential mechanisms of resistance. Novel approaches with regard to hormone therapy are also discussed. The use of GnRH-agonists and GnRH-antagonists yields efficacy that is likely equivalent in resulting in testosterone suppression. While the side-effect profile with ADT are generally equivalent, effects on cardiovascular morbidity may be improved with the use of oral relugolix though this is noted with caution since the cardiovascular side-effects were a result of secondary subgroup analyses. The choice of ADT hinges upon cost, availability, ease of administration, and preference amongst physicians and patients alike.


    Eun-Mi Yu, Jeanny B Aragon-Ching. Advances with androgen deprivation therapy for prostate cancer. Expert opinion on pharmacotherapy. 2022 Jun;23(9):1015-1033

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35108137

    View Full Text